439 related articles for article (PubMed ID: 18571789)
1. Tranilast, an antifibrogenic agent, ameliorates a dietary rat model of nonalcoholic steatohepatitis.
Uno M; Kurita S; Misu H; Ando H; Ota T; Matsuzawa-Nagata N; Kita Y; Nabemoto S; Akahori H; Zen Y; Nakanuma Y; Kaneko S; Takamura T
Hepatology; 2008 Jul; 48(1):109-18. PubMed ID: 18571789
[TBL] [Abstract][Full Text] [Related]
2. Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis.
Ota T; Takamura T; Kurita S; Matsuzawa N; Kita Y; Uno M; Akahori H; Misu H; Sakurai M; Zen Y; Nakanuma Y; Kaneko S
Gastroenterology; 2007 Jan; 132(1):282-93. PubMed ID: 17241878
[TBL] [Abstract][Full Text] [Related]
3. Olmesartan ameliorates a dietary rat model of non-alcoholic steatohepatitis through its pleiotropic effects.
Kurita S; Takamura T; Ota T; Matsuzawa-Nagata N; Kita Y; Uno M; Nabemoto S; Ishikura K; Misu H; Ando H; Zen Y; Nakanuma Y; Kaneko S
Eur J Pharmacol; 2008 Jul; 588(2-3):316-24. PubMed ID: 18501344
[TBL] [Abstract][Full Text] [Related]
4. Prevention of free fatty acid-induced hepatic lipotoxicity by carnitine via reversal of mitochondrial dysfunction.
Jun DW; Cho WK; Jun JH; Kwon HJ; Jang KS; Kim HJ; Jeon HJ; Lee KN; Lee HL; Lee OY; Yoon BC; Choi HS; Hahm JS; Lee MH
Liver Int; 2011 Oct; 31(9):1315-24. PubMed ID: 22093454
[TBL] [Abstract][Full Text] [Related]
5. Hepatic AdipoR2 signaling plays a protective role against progression of nonalcoholic steatohepatitis in mice.
Tomita K; Oike Y; Teratani T; Taguchi T; Noguchi M; Suzuki T; Mizutani A; Yokoyama H; Irie R; Sumimoto H; Takayanagi A; Miyashita K; Akao M; Tabata M; Tamiya G; Ohkura T; Hibi T
Hepatology; 2008 Aug; 48(2):458-73. PubMed ID: 18666257
[TBL] [Abstract][Full Text] [Related]
6. Upregulation of osteopontin expression is involved in the development of nonalcoholic steatohepatitis in a dietary murine model.
Sahai A; Malladi P; Melin-Aldana H; Green RM; Whitington PF
Am J Physiol Gastrointest Liver Physiol; 2004 Jul; 287(1):G264-73. PubMed ID: 15044174
[TBL] [Abstract][Full Text] [Related]
7. IFN-γ deficiency attenuates hepatic inflammation and fibrosis in a steatohepatitis model induced by a methionine- and choline-deficient high-fat diet.
Luo XY; Takahara T; Kawai K; Fujino M; Sugiyama T; Tsuneyama K; Tsukada K; Nakae S; Zhong L; Li XK
Am J Physiol Gastrointest Liver Physiol; 2013 Dec; 305(12):G891-9. PubMed ID: 24136786
[TBL] [Abstract][Full Text] [Related]
8. Free cholesterol accumulation in hepatic stellate cells: mechanism of liver fibrosis aggravation in nonalcoholic steatohepatitis in mice.
Tomita K; Teratani T; Suzuki T; Shimizu M; Sato H; Narimatsu K; Okada Y; Kurihara C; Irie R; Yokoyama H; Shimamura K; Usui S; Ebinuma H; Saito H; Watanabe C; Komoto S; Kawaguchi A; Nagao S; Sugiyama K; Hokari R; Kanai T; Miura S; Hibi T
Hepatology; 2014 Jan; 59(1):154-69. PubMed ID: 23832448
[TBL] [Abstract][Full Text] [Related]
9. Regulation of synthesis and oxidation of fatty acids by adiponectin receptors (AdipoR1/R2) and insulin receptor substrate isoforms (IRS-1/-2) of the liver in a nonalcoholic steatohepatitis animal model.
Matsunami T; Sato Y; Ariga S; Sato T; Shimomura T; Kashimura H; Hasegawa Y; Yukawa M
Metabolism; 2011 Jun; 60(6):805-14. PubMed ID: 20846698
[TBL] [Abstract][Full Text] [Related]
10. Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis.
Witek RP; Stone WC; Karaca FG; Syn WK; Pereira TA; Agboola KM; Omenetti A; Jung Y; Teaberry V; Choi SS; Guy CD; Pollard J; Charlton P; Diehl AM
Hepatology; 2009 Nov; 50(5):1421-30. PubMed ID: 19676126
[TBL] [Abstract][Full Text] [Related]
11. Adenovirus-mediated peroxisome proliferator activated receptor gamma overexpression prevents nutritional fibrotic steatohepatitis in mice.
Nan YM; Han F; Kong LB; Zhao SX; Wang RQ; Wu WJ; Yu J
Scand J Gastroenterol; 2011 Mar; 46(3):358-69. PubMed ID: 20969493
[TBL] [Abstract][Full Text] [Related]
12. Reduced expression of peroxisome proliferator-activated receptor-alpha may have an important role in the development of non-alcoholic fatty liver disease.
Yeon JE; Choi KM; Baik SH; Kim KO; Lim HJ; Park KH; Kim JY; Park JJ; Kim JS; Bak YT; Byun KS; Lee CH
J Gastroenterol Hepatol; 2004 Jul; 19(7):799-804. PubMed ID: 15209628
[TBL] [Abstract][Full Text] [Related]
13. Pigment Epithelium-Derived Factor (PEDF) Prevents Hepatic Fat Storage, Inflammation, and Fibrosis in Dietary Steatohepatitis of Mice.
Yoshida T; Akiba J; Matsui T; Nakamura K; Hisamoto T; Abe M; Ikezono Y; Wada F; Iwamoto H; Nakamura T; Koga H; Yamagishi SI; Torimura T
Dig Dis Sci; 2017 Jun; 62(6):1527-1536. PubMed ID: 28365916
[TBL] [Abstract][Full Text] [Related]
14. Telmisartan attenuates progression of steatohepatitis in mice: role of hepatic macrophage infiltration and effects on adipose tissue.
Kudo H; Yata Y; Takahara T; Kawai K; Nakayama Y; Kanayama M; Oya T; Morita S; Sasahara M; Mann DA; Sugiyama T
Liver Int; 2009 Aug; 29(7):988-96. PubMed ID: 19386026
[TBL] [Abstract][Full Text] [Related]
15. Activation of peroxisome proliferator-activated receptor alpha by dietary fish oil attenuates steatosis, but does not prevent experimental steatohepatitis because of hepatic lipoperoxide accumulation.
Larter CZ; Yeh MM; Cheng J; Williams J; Brown S; dela Pena A; Bell-Anderson KS; Farrell GC
J Gastroenterol Hepatol; 2008 Feb; 23(2):267-75. PubMed ID: 17868330
[TBL] [Abstract][Full Text] [Related]
16. Aerobic exercise training in the treatment of non-alcoholic fatty liver disease related fibrosis.
Linden MA; Sheldon RD; Meers GM; Ortinau LC; Morris EM; Booth FW; Kanaley JA; Vieira-Potter VJ; Sowers JR; Ibdah JA; Thyfault JP; Laughlin MH; Rector RS
J Physiol; 2016 Sep; 594(18):5271-84. PubMed ID: 27104887
[TBL] [Abstract][Full Text] [Related]
17. Kupffer cell depletion attenuates leptin-mediated methoxamine-stimulated portal perfusion pressure and thromboxane A2 release in a rodent model of NASH-cirrhosis.
Yang YY; Huang YT; Tsai TH; Hou MC; Lee FY; Lee SD; Lin HC
Clin Sci (Lond); 2012 Dec; 123(12):669-80. PubMed ID: 22734967
[TBL] [Abstract][Full Text] [Related]
18. Role of adipocytokines in hepatic fibrogenesis.
Ikejima K; Okumura K; Kon K; Takei Y; Sato N
J Gastroenterol Hepatol; 2007 Jun; 22 Suppl 1():S87-92. PubMed ID: 17567476
[TBL] [Abstract][Full Text] [Related]
19. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Staels B; Rubenstrunk A; Noel B; Rigou G; Delataille P; Millatt LJ; Baron M; Lucas A; Tailleux A; Hum DW; Ratziu V; Cariou B; Hanf R
Hepatology; 2013 Dec; 58(6):1941-52. PubMed ID: 23703580
[TBL] [Abstract][Full Text] [Related]
20. Effect of losartan on early liver fibrosis development in a rat model of nonalcoholic steatohepatitis.
Ibañez P; Solis N; Pizarro M; Aguayo G; Duarte I; Miquel JF; Accatino L; Arrese M
J Gastroenterol Hepatol; 2007 Jun; 22(6):846-51. PubMed ID: 17565640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
